1. Introduction {#sec1-molecules-22-00343}
===============

Malaria is a severe and life-threatening disease caused by *Plasmodium* parasites that are spread to humans through bites of infected *Anopheles* mosquitoes. *Plasmodium* sporozoites injected into the bloodstream travel to the liver, where they are transformed into merozoites. They later re-enter the bloodstream, attacking the red blood cells where they begin the asexual replication. A few of these merozoites develop into sexual forms---gametocytes---which are being taken up by mosquitos during blood feeding, thus completing their life cycle \[[@B1-molecules-22-00343]\]. This suggests that numerous stages of the life cycle of *Plasmodium* parasite could be potential drug targets for development of new antimalarials.

According to the 2015 World Health Organization (WHO) report it is estimated that 214 million cases of malaria occurred globally and the disease led to 438,000 deaths \[[@B2-molecules-22-00343]\]. As artemisinin resistance has spread, posing a threat to malaria control \[[@B3-molecules-22-00343]\], in order to prevent progression to life-threatening malaria artemisinin-based combination therapies (ACTs) have been recommended by the WHO \[[@B4-molecules-22-00343]\]. A vaccine has yet to be discovered \[[@B5-molecules-22-00343]\] and taking into account the constant loss of therapeutic efficacy due to the drug resistant strains, there is an urgent need for the discovery of new targets and treatments for malaria. Widespread chloroquine (CQ) resistance is largely attributable to mutations in the vacuole transmembrane protein (PfCRT) protein \[[@B6-molecules-22-00343],[@B7-molecules-22-00343]\], found in the membrane of the digestive vacuole where hemoglobin digestion takes place.

A number of potential drug targets for novel antimalarials are known so far, most of them parasite proteins, such as *Plasmodium falciparum* enoyl-acyl carrier protein reductase \[[@B8-molecules-22-00343],[@B9-molecules-22-00343],[@B10-molecules-22-00343]\], fatty acid synthase (PfFAS) \[[@B11-molecules-22-00343]\], *N*-myristoyltransferase (NMT) \[[@B12-molecules-22-00343],[@B13-molecules-22-00343]\], hexose transporter (PfHT1) \[[@B14-molecules-22-00343],[@B15-molecules-22-00343],[@B16-molecules-22-00343]\], serine hydroxymethyltransferase (SHMT) \[[@B17-molecules-22-00343]\], histone deacetylase \[[@B18-molecules-22-00343]\], and many others. It is unclear if inhibition of these enzymes is the only mechanism of action (MOA) through which novel drugs inhibit parasite growth, but they are important in discovering enzyme function and metabolic pathways. Aminoquinolines, such as chloroquine, are well-known antimalarials. One of the hypotheses of their MOA is the accumulation in the parasite food vacuole, leading to inhibition of hemozoin formation. The toxic effect of free hematin containing ferriprotoporphyrin IX system is suppressed by "polymerization" into hemozoin; therefore, drugs that act as inhibitors of hematin sequestration are involved in the death of the parasite \[[@B19-molecules-22-00343]\]. On the other hand, molecules that contain benzothiophene cores have an important role in medicinal chemistry due to their various biological properties, including antibacterial, antifungal and antitubercular activities \[[@B20-molecules-22-00343]\]. They also act as inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK2) \[[@B21-molecules-22-00343],[@B22-molecules-22-00343]\], C~17,20~-lyase inhibitors \[[@B23-molecules-22-00343]\], liver receptor homolog-1 (LRH-1) antagonists \[[@B24-molecules-22-00343]\], inhibitors of tyrosine phosphatase 1B and antihyperglycemic agents \[[@B25-molecules-22-00343]\]. Regarding antimalarial activity, only one series of benzothiophene derivatives was evaluated and showed IC~50~ values up to 0.16 μM for *P. falciparum* 3D7 strain and inhibited parasite growth up to 65% at 50 mg/kg/day × 4 days in *P. berghei* infected mice \[[@B26-molecules-22-00343]\].

Now, we report on the efficacy of aminoquinolines coupled to benzothiophene and thiophene rings in inhibiting *Plasmodium falciparum* parasite growth and compare the obtained results with CQ and previously reported related thiophene and benzothiophene-based 4-amino-7-chloroquinoline derivatives \[[@B27-molecules-22-00343],[@B28-molecules-22-00343]\], as well as other antimalarial benzothiophene derivatives.

The new series possesses an additional phenylene linker between aminoquinoline and benzothiophene/thiophene moieties ([Figure 1](#molecules-22-00343-f001){ref-type="fig"}), and the influence of the extra π-system on antiplasmodial activity was analyzed taking into account the influence of different methylene linkers.

2. Results {#sec2-molecules-22-00343}
==========

2.1. Chemistry {#sec2dot1-molecules-22-00343}
--------------

The syntheses of the aminoquinoline antimalarials with a benzothiophene carrier were executed using procedures we developed earlier. Derivatives **8**, **9**, **12** and **13** were obtained by reductive amination, starting from the corresponding aldehydes ([Scheme 1](#molecules-22-00343-sch001){ref-type="scheme"}).

Substituted benzothiophene cores were synthesized starting from commercially available difluoro- or bromofluorobenzaldehyde. Bromination of benzothiophene core afforded C(3) substituted products **17**, **18** and **19** in good yields (\>80%, [Scheme 2](#molecules-22-00343-sch002){ref-type="scheme"}), which were further coupled to 4-formylphenylboronic acid via Suzuki reactions to give the aldehydes **20**, **21** and **22**. These fragments are used in the key reductive amination reaction to prepare a diverse set of methylene-linked *P. falciparum* inhibitors. It is interesting to note that aldehydes **20** and **22** were obtained in good yields (88% and 76%, respectively), in contrast to **21** (37%). Finally, the reductive amination afforded target compounds **23**--**26** and **28**--**32** in 19%--77% isolated yield after column purification. In addition, compound **26** was methylated and gave **27** in moderate yield.

In the thiophene series, the key intermediate, aldehyde **36**, was synthesized in few steps starting from commercially available 2-bromothiophene (**33**) as follows: 4-(thiophen-2-yl)benzonitrile (**34**) was obtained from 2-bromothiophene by Suzuki coupling with 4-cyanophenylboronic acid using PdO hydrate as a catalyst ([Scheme 3](#molecules-22-00343-sch003){ref-type="scheme"}) \[[@B29-molecules-22-00343]\]. Subsequent bromination of thiophene **34** at C(5) position and additional Suzuki reaction with 4-formyphenylboronic acid afforded **36** in excellent yield (92%). After submitting **36** to reductive amination reactions with different aminoquinolines, the target aminoquinoline derivatives **37**--**44** were obtained in 26%--59% isolated yield. The compound **45** was further methylated providing derivative **46** with a tertiary amino group ([Scheme 3](#molecules-22-00343-sch003){ref-type="scheme"}).

To examine the significance of the cyano group for antiplasmodial potency, the terminal acetylenic derivative **52** was prepared ([Scheme 4](#molecules-22-00343-sch004){ref-type="scheme"}). 2-Bromothiophene (**33**) was coupled with 4-formylphenylboronic acid to afford **47**. Brominated product **48** obtained by reaction of **47** with NBS in THF was further submitted to Suzuki coupling with the 4-bromophenylboronic acid to afford the bromo aldehyde **49**, which was converted in the next step to **50** by Sonogashira coupling with ethynyltrimethylsilane applying microwave irradiation. The final acetylene derivative **52** was obtained after reductive amination of **50** that was followed by removal of trimethylsilyl group under basic conditions.

All tested compounds were fully characterized and their purity was \>95% (as determined by High performance liquid chromatography (HPLC)). Full details are given in the [Supplementary Materials](#app1-molecules-22-00343){ref-type="app"}.

2.2. In Vitro Antiplasmodial Activity {#sec2dot2-molecules-22-00343}
-------------------------------------

The antimalarial candidates were tested in vitro for their antiplasmodial activity against three *P. falciparum* strains: D6 (CQ susceptible (CQS) strain), W2 (CQ resistant (CQR) strain), and TM91C235 (Thailand, a multidrug-resistant (MDR) strain), using the Malaria SYBR Green Fluorescence Assay, a microtiter drug sensitivity assay that uses the intercalation of SYBR Green into malaria DNA as a measure of blood stage *P. falciparum* parasite proliferation in the presence of antimalarial compounds. This assay is performed as a dose response (12 two-fold serial dilutions) to obtain a calculated IC~50~ determination \[[@B30-molecules-22-00343]\]. CQ and mefloquine (MFQ) were used as positive controls ([Table 1](#molecules-22-00343-t001){ref-type="table"} and [Table 2](#molecules-22-00343-t002){ref-type="table"}).

As a general remark, to our content, all synthesized compounds were more active than CQ against the CQR W2 strain. Importantly, compounds **29**, **30** and **31** were as active as CQ against the CQS D6 strain (and had higher activity against W2 and C235 strains), while **28** was two times more active than CQ against the D6 strain. Comparison of in vitro antiplasmodial activities of fluoro and cyano analogues **26** with **29**, and **24** with **30**, clearly indicate that both cyano derivatives show significantly higher activities against CQS D6 strain. To analyze the effect of the cyano group in different positions of the benzothiophene core, we synthesized the pair of homologs **28**, **30**, and **31**, **32**, respectively. The compounds with cyano group at C(5) position were more potent than their C(6) isomers; it was also noticed that the shorter linker *n* = 2, instead of *n* = 4, was more favorable for antiplasmodial activity against D6 strain (**28** vs. **30**, **31** vs. **32**).

Unlike benzothiophenes, the compounds of the thiophene series were found to generally exhibit higher in vitro activity against CQR W2 than against CQS D6 strain ([Table 2](#molecules-22-00343-t002){ref-type="table"}). We found it indicative that all derivatives in this series bearing cyano group were more active against MDR C235 strain in comparison to CQ, among which **41**, **42**, **44**, and **46** showed higher potency than MFQ as well. In addition, all tested C(7) chloro derivatives were more active than the respective des-chloro aminoquinolines against CQR W2 strain, e.g., **41** vs. **44** (13 nM vs. 74 nM). The effect of the cyano group of this series was additionally confirmed by comparison of its antimalarial activity to the activity of the respective acetylene analogue **52**, suggesting that cyano substituent may play an important role in the antiplasmodial activity of these derivatives.

3. Discussion {#sec3-molecules-22-00343}
=============

To investigate possible toxicity issues, the synthesized compounds were evaluated in vitro against a human hepatoma cell line (HepG2). The range of their activity falls within 1976--30605 nM, significantly higher in comparison to their respective antimalarial activities ([Table 1](#molecules-22-00343-t001){ref-type="table"} and [Table 2](#molecules-22-00343-t002){ref-type="table"}).

Among all examined derivatives, the compounds **25**, **42**, and **46** have been chosen for in vivo evaluation since they showed significant activities against W2 clone in vitro ([Table 1](#molecules-22-00343-t001){ref-type="table"} and [Table 2](#molecules-22-00343-t002){ref-type="table"}, RI values), which is in sharp contrast to CQ. In a separate host toxicity study, benzothiophene **25** was subjected to in vivo toxicity evaluation. At the 160 mg/kg/day × 3 days dose, **25** proved to be non-toxic, as all 5 mice survived 30 days after administration and showed normal appearance and behavior. Yet, using a modified Thompson test model \[[@B31-molecules-22-00343]\], administering **25** at the same concentration of 160 mg/kg/day × 3 days to C57Bl6 female mice infected with 1 × 10^6^ *P. berghei* parasites, unfortunately led to death of 3 out of 4 mice, with only one surviving 31 days but with parasitemia. In this test model, *P. berghei* infected mice were treated with aminoquinolines suspended in 0.5% hydroxyethylcellulose-0.1% Tween 80 and administered per os (p.o.) once per day on days 3--5 postinfection ([Table 3](#molecules-22-00343-t003){ref-type="table"}).

Regarding thiophene derivatives, they were all well tolerated by Hep G2 cells, possessing IC~50~ \> 2000 nM. However, rather low selectivity indices were calculated for all derivatives (SI~HepG2/D6~ = 30--624) with an exception of derivative **43**, SI ~HepG2/D6~ \> 2000. In a host toxicity study at the concentration of 160 mg/kg × 3 days, compounds **42** and **46** with the longest methylene linker (eight methylene groups), proved to be non-toxic (all 5 mice survived). The compounds were further subjected to in vivo evaluation, using the modified Thompson test model, at 160 mg/kg/day × 3 days for **42**, and at 80 and 40 mg/kg/day × 4 days for **46**. Under applied treatment conditions, three sets of 5 infected mice died of malaria. Derivative **46** enabled one mouse survival until day 25 (D25) at both administered doses, while compound **42** provided survival with high level of parasitemia until day 24 (D24) at a higher dose ([Table 3](#molecules-22-00343-t003){ref-type="table"}).

It is important to be aware that direct correlation of in vitro and in vivo results is not always justified. One of many examples is our previously reported compound **1** \[[@B27-molecules-22-00343]\] ([Figure 2](#molecules-22-00343-f002){ref-type="fig"}), which was examined for its antimalarial activity in vivo, despite a relatively low SI (282). Surprisingly, compound **1** cured 5/5 mice using a modified Thompson test ([Figure 3](#molecules-22-00343-f003){ref-type="fig"}, [Table 3](#molecules-22-00343-t003){ref-type="table"}) and cleared all parasites on day 7 (D7) (parasitemia before treatment was 0.3%--0.9%, and at the end of the study all 5 mice were parasite negative). The same compound was assessed in a dose response test in which *P. berghei* infected mice were treated per os (p.o.) for 4 days, starting with day 3 postinfection. Unfortunately, at all three applied doses (80, 40 and 20 mg/kg/day) benzothiophene **1** did not clear the parasites ([Table 3](#molecules-22-00343-t003){ref-type="table"}). There was no detectable parasitemia up to day 11 at a dose as low as 40 mg/kg/day**;** however, recrudescence occurred between day 11 (D11) and day 14 (D14). In vivo activity results for **1** are summarized on [Figure 3](#molecules-22-00343-f003){ref-type="fig"}. On the other hand, compound **53** \[[@B27-molecules-22-00343]\] with a propylene linker, which showed much more promising SI index (1111), proved to be toxic at concentration of 160 mg/kg/day, thus it was not evaluated in vivo ([Figure 2](#molecules-22-00343-f002){ref-type="fig"}).

Parasite clearance provided by compound **1** with a 160 mg/kg/day × 3 days dose regimen, was further examined at the molecular level by polymerase chain reaction (PCR) \[[@B32-molecules-22-00343]\]. Briefly, genomic DNA was extracted from the blood and liver of experimental animals using the DNeasy blood and tissue kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The primers and corresponding TaqMan (Applied BioSystems. Foster City, CA, USA) probe amplify and detect a highly conserved region of the 18S rRNA gene of the genus *Plasmodium*. Pure *P. berghei* gDNA samples were used as positive controls. Both blood and tissue samples of all 5 mice proved to be negative for *P. berghei* DNA ([Figure 4](#molecules-22-00343-f004){ref-type="fig"}).

The possible mechanism of action of compound **1** could include inhibition of β-hematin formation, since this compound showed a low IC~50~ value of 0.34 \[[@B33-molecules-22-00343]\], which is 3.7 times lower than for CQ.

4. Materials and Methods {#sec4-molecules-22-00343}
========================

4.1. Chemistry {#sec4dot1-molecules-22-00343}
--------------

### 4.1.1. General Experimental Procedures {#sec4dot1dot1-molecules-22-00343}

Melting points were determined on a Boetius PHMK apparatus (Carl Zeiss, Germany) and were not corrected. IR spectra were recorded on a Nicolet 6700 Fourier-transformed infrared (FT-IR) diamond crystal spectrophotometer (Thermo-Scientific, Waltham, MA, USA). ^1^H- and ^13^C-NMR spectra were recorded on a Ultrashield Advance III spectrometer (at 500 and 125 MHz, respectively, Bruker, Billerica, MA, USA) and Gemini-200 spectrometer (at 50 MHz for ^13^C-NMR spectra, Varian, Palo Alto, CA, USA), in the indicated solvents (vide infra) using tetramethylsilane as the internal standard. Chemical shifts are expressed in ppm (δ) values and coupling constants (*J*) in Hz. High-resolution electrospray ionization mass spectrometry (ESI--MS, HRMS) spectra of the synthesized compounds were acquired on a 1200 Series instrument (Agilent Technologies, Santa Clara, CA, USA) equipped with a Zorbax Eclipse Plus C18 (100 × 2.1 mm i.d. 1.8 μm) column and diode array detector (DAD, 190--450 nm) in combination with a 6210 Time-of-Flight LC/MS instrument in positive ion mode. The samples were dissolved in MeOH (HPLC grade). The selected values were as follows: capillary voltage 4 kV; gas temperature 350 °C; drying gas 12 L·min^-1^; nebulizer pressure 45 psig; fragmentator voltage 70 V. Gas chromatography tandem mass spectrometry (GC-MS) analyses were performed on an Agilent 7890A GC (Agilent) system equipped with a 5975C inert XL EI/CI MSD and a flame ionization detector (FID) connected by capillary flow technology through a 2-way splitter with make-up gas. An HP-5 MS capillary column (Agilent Technologies, 25 mm i.d., 30 m length, 0.25 μm film thickness) was used. The flash chromatography was performed on a Biotage SP1 system (Biotage AB, Uppsala, Sweden) equipped with UV detector and FLASH 12+, FLASH 25+ or FLASH 40+ columns charged with KP-SIL (40--63 µm, pore diameter 60 Å), KP-C18-HS (40--63 µm, pore diameter 90 Å) or KP-NH (40--63 µm, pore diameter 100 Å) as an adsorbent.

### 4.1.2. Method A---General Procedure for Reductive Amination for Compounds **8**, **9**, **12**, **13**, **23**--**26**, **28**--**32**, **37**--**45**, **51** {#sec4dot1dot2-molecules-22-00343}

Amine (1.5 eq.) and appropriate aldehyde (1 eq.) were dissolved in MeOH/CH~2~Cl~2~ mixture (2:1 *v*:*v*), AcOH glac (1.5 eq.) was added, and the mixture was stirred under an Ar atmosphere at r.t. After 3 h, NaBH~4~ (6 eq.) was added, and stirring was continued for another 18 h. Solvent was removed under reduced pressure, and the residue was dissolved in CH~2~Cl~2~. The organic layer was washed with 2M NH~4~OH, water and then extracted with CH~2~Cl~2~. The combined organic layers were washed with brine and dried over anhydrous Na~2~SO~4~. Finally, the solvent was evaporated under reduced pressure.

### 4.1.3. Method B---General Experimental Procedure for Bromination for Compounds **17**--**19**, **35** {#sec4dot1dot3-molecules-22-00343}

Substituted benzothiophene (1 eq.) was dissolved in 1,2-dichloroethane. A solution of bromine (1.12 eq.) in 1,2-dichloroethane (CH~2~Cl~2~ for **17**) was slowly added to the reaction mixture at 0 °C, then warmed to r.t., and stirred for 2 h. Reaction progress was monitored by thin-layer chromatography (TLC, reverse phase silica gel, MeOH). Aqueous Na~2~S~2~O~3~ solution was added, and the desired product was extracted with CH~2~Cl~2~. Combined organic layers were washed with brine, and dried over anhydrous Na~2~SO~4~. After filtration, the solvent was removed under reduced pressure. The product was purified using column chromatography. \[[@B34-molecules-22-00343]\]

### 4.1.4. Method C---General Procedure for Suzuki Coupling for Compounds **20**--**22** {#sec4dot1dot4-molecules-22-00343}

A suspension of Pd(OAc)~2~ (5.00 mol %) and SPhos (20.0 mol %) in DME was purged with Ar and stirred at r.t. for 10 mins. Brominated benzothiophene (1 eq.) in DME and 2 M Na~2~CO~3~ were then added. After 5 min, 4-formylphenylboronic acid (1.2 eq.) in EtOH was added. The mixture is once more purged with Ar and heated in a sealed vessel in microwave reactor at 100 °C for 2 h. Reaction mixture was filtered through Celite and transferred to a separation funnel. Water was added and extracted with CH~2~Cl~2~. Combined organic layers were washed with brine and dried over anhydrous Na~2~SO~4~. After filtration, the solvent was removed under reduced pressure. The product was purified using column chromatography.

### 4.1.5. Method D---General Procedure for Synthesis of Aminoquinolines **AQ88**, **AQ9** and **AQ10** {#sec4dot1dot5-molecules-22-00343}

A mixture of 4-chloroquinoline or 4,7-dichloroquinoline (1 eq.) and an appropriate diamine (5 eq.) were subjected to microwave irradiation using an Initiator 2.5 apparatus (Biotage) for 15 mins at 80 °C, followed by 30 mins at 95 °C and then 2 h at 140 °C. After cooling to room temperature 0.1 M aqueous NaOH was added and then extracted with CH~2~Cl~2~. Combined organic layers were dried over anhydrous Na~2~SO~4~. After filtration, the solvent was removed under reduced pressure. The crude product was subjected to silica-gel column chromatography using CH~2~Cl~2~/MeOH (NH~3~ satd.) as eluent to afford the final compound.

### 4.1.6. Method E---General Procedure for *N*-Methylation of Aminoquinolines for Compounds **27** and **46** {#sec4dot1dot6-molecules-22-00343}

To a stirred solution of aminoquinolines (1 eq.) in MeOH containing 37% aqueous formaldehyde (2 eq.) was added mixture of ZnCl~2~ (2 eq.) and NaHB~3~CN (4 eq.) in MeOH. After the reaction mixture was stirred at r.t. for 4 h, the solution was taken up in 0.1 M NaOH and most of the MeOH was evaporated under reduced pressure. Aqueous solution was extracted with CH~2~Cl~2~, the combined extracts were washed with water and brine and dried over anhydrous Na~2~SO~4~. The solvent was evaporated under reduced pressure. \[[@B35-molecules-22-00343]\]

### 4.1.7. Method F---General Procedure for the Suzuki Coupling Reaction Using PdO × 1.4 H~2~O for Compounds **34**, **36** {#sec4dot1dot7-molecules-22-00343}

An appropriate aryl-bromide (1 eq.) was added to the mixture of arylboronic acid (1.2 eq.), catalyst PdO × 1.4 H~2~O (0.01--0.05 eq.), K~2~CO~3~ (1.2 eq.) and ethanol/H~2~O (3:1 *v*/*v*). The mixture was stirred at 60 °C for 5 h, then diluted with water and extracted with CH~2~Cl~2~. The combined organic layers were washed with brine and dried over anhydrous Na~2~SO~4~. After filtration, the solvent was removed under reduced pressure. The product was purified using silica gel flash chromatography \[[@B29-molecules-22-00343]\].

### 4.1.8. Method G---General Procedure for the Suzuki Coupling in MeOH/Toluene for Compounds **47**, **49** {#sec4dot1dot8-molecules-22-00343}

A solution of Pd(OAc)~2~ (0.05 eq.) and PPh~3~ (0.2 eq.) in toluene was stirred at r.t. under an argon atmosphere for 10 mins. After that, the solution of an appropriate aryl-bromide (1 eq.), an appropriate arylboronic acid (1.1 eq.) and 2M aq. Na~2~CO~3~ (2 eq.) in MeOH and toluene was added. The mixture was stirred at 110 °C under an argon atmosphere for 3 h. The reaction work up method is provided for each compound.

*N*-(7-Chloroquinolin-4-yl)ethane-1,2-diamine (**AQ2**), *N*-(7-chloroquinolin-4-yl)propane-1,3-diamine (**AQ3**), *N*-(7-chloroquinolin-4-yl)butane-1,4-diamine (**AQ4**), *N*-(7-chloroquinolin-4-yl)pentane-1,5-diamine (**AQ5**), *N*-(7-chloroquinolin-4-yl)hexane-1,6-diamine (**AQ6**), *N*-(quinolin-4-yl)propane-1,3-diamine (**AQ7**), *N*-(quinolin-4-yl)butane-1,4-diamine (**AQ8**), were prepared according to known procedures \[[@B36-molecules-22-00343],[@B37-molecules-22-00343],[@B38-molecules-22-00343],[@B39-molecules-22-00343]\].

Full details are given in the [Supplementary Materials](#app1-molecules-22-00343){ref-type="app"}.

4.2. In Vitro Antiplasmodial Activity {#sec4dot2-molecules-22-00343}
-------------------------------------

Synthesized aminoquinolines were screened in vitro against *P. falciparum* strains: CQ and MFQ susceptible strain D6 (clone of Sierra Leone/UNC isolate), CQ resistant but MFQ susceptible strain W2 (clone of Indochina isolate), and CQ and MFQ resistant strain TM91C235 (clone of South East Asian isolate) using the Malaria SYBR Green Fluorescence Assay. Full method details are given in [Supplementary Materials](#app1-molecules-22-00343){ref-type="app"} I. Assessment of compound toxicity in a HepG2 (hepatocellular carcinoma) cell line followed the protocol described in Ref. \[[@B40-molecules-22-00343]\].

4.3. In Vivo Antiplasmodial Activity and Toxicity {#sec4dot3-molecules-22-00343}
-------------------------------------------------

The *P. berghei* (ANKA) mouse efficacy tests were conducted using a modified version of the Thompson test. Groups of five mice were inoculated intraperitoneally with erythrocytes infected with *P. berghei* on day 0. Drugs were suspended in 0.5% hydroxyethylcellulose-0.1% Tween 80 and administered orally once a day beginning on day 3 post infection. Dosings are given in [Table 3](#molecules-22-00343-t003){ref-type="table"}. All untreated infected (control) mice showed parasitemia on day 3, which reached levels between 11.2% and 30% on day 6 and succumbed to the infection on day 6--8. Therefore, the test was considered valid. Cure was defined as survival (with no parasitemia) until day 31 post-treatment. Parasitemia was determined by thin-blood Giemsa-stained smears prepared from mice tail blood of each animal on days 0, 3, 6, 10, 13, 17, 20, 24, 27, and 31 (postinfection). The slides were examined under a light microscope.

In a separate host toxicity study, groups of five healthy mice were administered 160 mg/kg/day × 3 days of the investigational compounds and individually monitored for behavior and appearance two times a day for 31 days. No toxicity was defined as survival past day 31 with no overt clinical manifestations of toxicity (changes in behavior and appearance).

The study followed the International Guiding Principles for biomedical research involving animals, and was reviewed by a local Ethics Committee and approved by the Veterinary Directorate at the Ministry of Agricultutre and Environmental Protection of Serbia (decision no. 323-07-02444/2014-05/1).

4.4. Genomic DNA Extraction and qPCR Analysis {#sec4dot4-molecules-22-00343}
---------------------------------------------

### 4.4.1. DNA Extraction {#sec4dot4dot1-molecules-22-00343}

Genomic DNA was extracted from the blood and liver of experimental animals using the DNeasy blood and tissue kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Briefly, mice alive past day 31 with complete parasite clearance were sacrificed. Next, between 300 and 500 μL of blood was removed after heart puncture and the organs were removed, rinsed with dPBS and homogenized. The liver was homogenized using mechanical disruption and then subjected to proteinase K digestion. Approximately 100 μL of sample was used per each spin column for gDNA extraction.

### 4.4.2. Real Time PCR {#sec4dot4dot2-molecules-22-00343}

Briefly, the primers and corresponding TaqMan probe amplify and detect a highly conserved region of the 18S rRNA gene of the genus *Plasmodium*. The primer and probe sequences were as follows: forward primer [Plasmo 1]{.ul}: 5-GTTAAGGGAGTGAAGACGA TCAGA-3; reverse primer [Plasmo 2]{.ul}: 5-AACCCAAAGACTTTGATTTC TCATAA-3; TaqMan probe [Plasprobe]{.ul}: 5-*FAM*-ACCGTCGTAA TCTTAACCAT AAACTATGCC GACTAG-*TAMRA*-3. Each 20μL reaction contained 1× Maxima Probe qPCR Master Mix (Thermo Fisher Scientific, Waltham, MA, USA), 200 nM of each primer, 50 nM probe, 1U UNG (Thermo Fisher Scientific) and 3 μL template gDNA. The following PCR conditions were used: one holding step at 50 °C for 2 min, one holding step at 95 °C for 10 min, then 45 cycles of 95 °C for 15 s, 60 °C for 1 min. The PCR was performed in a StepOne Plus instrument (Applied BioSystems). Samples starting with Ct40 were considered negative. A positive (*P. berghei* gDNA) and negative control (H~2~O) were included in each run \[[@B32-molecules-22-00343]\].

5. Conclusions {#sec5-molecules-22-00343}
==============

Benzothiophenes presented in this paper, in comparison to compounds discussed in \[[@B26-molecules-22-00343]\] showed improved activities against the CQS strain, with potencies against D6 of IC~50~ = 6 nM, and cured 5/5 *P. berghei* infected mice dosed per os (p.o.) at 160 mg/kg/day × 3 days. However, comparing the two series of benzothiophenes (and thiophenes), with and without the phenyl linker, we found that introducing the phenyl linker did not improve the in vitro activity of the first series of aminoquinolines \[[@B27-molecules-22-00343]\] In both benzothiophene series, all compounds were more active against the CQS strain D6, than against strains CQR W2 and MDR TM91C235, with the sole exception of **25** which was more active against the W2 strain. As for thiophene series---**37**--**42**, **44** and **46**---a very interesting feature was revealed: hypersensitivity to the resistant strains, with a resistance index of less than 1. This is in sharp contrast to chloroquine, thus indicating that further development of the series could provide us with antimalarials more powerful against CQR strains.
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Figures, Schemes and Tables
===========================

![Benzothiophene and thiophene based antimalarials **23**--**32**, **37**--**46** and **52**.](molecules-22-00343-g001){#molecules-22-00343-f001}

![Synthesis of benzothiophene derivatives **8**, **9**, **12** and **13**.](molecules-22-00343-sch001){#molecules-22-00343-sch001}

![Synthesis of benzothiophene derivatives **23**--**32** with the phenylene linker. SPhos = 2-Dicyclohexylphosphino-2′,6′-dimethoxybiphenyl‎; DME = 1,2-dimetoxyethane](molecules-22-00343-sch002){#molecules-22-00343-sch002}

![Synthesis of thiophene derivatives **37**--**46**.](molecules-22-00343-sch003){#molecules-22-00343-sch003}

![Synthesis of acetylene derivative **52**. NBS = *N*-bromosuccinimide; THF = tetrahydrofuran; DMF = *N*,*N*-dimethylformamide; MW = microwave irradiation; AQ10 = *N*-(quinolin-4-yl)octane-1,8-diamine.](molecules-22-00343-sch004){#molecules-22-00343-sch004}

![Antimalarial activity of compounds **1** and **53**. RBC---red blood cell.](molecules-22-00343-g002){#molecules-22-00343-f002}

![Effect of treatment with compound **1** at four dosage regimens (20, 40, 80, 160 mg/kg) on the survival of mice infected with *P. berghei* Antwerpen-Kasapa (ANKA) strain.](molecules-22-00343-g003){#molecules-22-00343-f003}

![Real time (quantitative) PCR (qPCR) analysis for compound **1.** Amplification curves for blood and tissues of five mice. Horizontal line represents threshold for amplification. All values \>40 Ct and amplification curves below threshold indicate absence of target DNA. The three amplification curves above threshold correspond to positive controls.](molecules-22-00343-g004){#molecules-22-00343-f004}

molecules-22-00343-t001_Table 1

###### 

In vitro antiplasmodial activity of benzothiophene derivatives.

  Structure     In Vitro Antimalarial Activity (*P. falciparum*, IC~50~, nM) ^a,b^   HepG2 ^f^ (IC~50~, nM)   SI ^g^ HepG2/D6   RI ^h^ W2/D6                
  ------------- -------------------------------------------------------------------- ------------------------ ----------------- -------------- ------ ----- ------
  **8**         ![](molecules-22-00343-i001.jpg)                                     20                       104               107            8867   440   5.2
  **9**         ![](molecules-22-00343-i002.jpg)                                     14                       191               205            4867   339   13.6
  **12**        ![](molecules-22-00343-i003.jpg)                                     21                       185               191            4477   211   8.8
  **13**        ![](molecules-22-00343-i004.jpg)                                     16                       201               177            2726   172   12.6
  **23**        ![](molecules-22-00343-i005.jpg)                                     28                       144               111            3825   136   5.1
  **24**        ![](molecules-22-00343-i006.jpg)                                     60                       277               242            2233   37    4.6
  **25**        ![](molecules-22-00343-i007.jpg)                                     71                       12                121            2087   29    0.2
  **26**        ![](molecules-22-00343-i008.jpg)                                     36                       55                45             2345   65    1.5
  **27**        ![](molecules-22-00343-i009.jpg)                                     29                       126               126            4998   173   4.3
  **28**        ![](molecules-22-00343-i010.jpg)                                     6                        188               129            2575   401   31.3
  **29**        ![](molecules-22-00343-i011.jpg)                                     13                       44                46             2413   192   3.4
  **30**        ![](molecules-22-00343-i012.jpg)                                     12                       81                51             1976   162   6.8
  **31**        ![](molecules-22-00343-i013.jpg)                                     13                       197               93             3577   276   15.2
  **32**        ![](molecules-22-00343-i014.jpg)                                     55                       102               29             2049   37    1.8
  **CQ ^i^**    ![](molecules-22-00343-i015.jpg)                                     15 (6)                   595 (5)           206 (5)                     39.7
  **MFQ ^i^**   ![](molecules-22-00343-i016.jpg)                                     23 (6)                   7 (5)             55 (5)                      0.3

^a^ Antiplasmodial IC~50~ values (nM) (Malaria SYBR Green Fluorescence Assay) for isolates and clones of *P. falciparum*; ^b^ All in vitro experiments were done as technical quadruplicates, mean values are given; ^c^ Chloroquine (CQ) susceptible *P. falciparum* African D6 clone; ^d^ Chloroquine (CQ) resistant *P. falciparum* Indochina W2 clone; ^e^ *P. falciparum* CQ, MFQ and pyrimethamine resistant TM91C235 strain (Thailand); ^f^ Hepatocellular carcinoma; ^g^ Selectivity index; ^h^ Resistance index; ^i^ Control drugs: CQ as diphosphate; MFQ as HCl salt (number of replicates given in parentheses).

molecules-22-00343-t002_Table 2

###### 

In vitro antiplasmodial activity of thiophene derivatives.

  Structure     In Vitro Antimalarial Activity (*P. falciparum*, IC~50~, nM) ^a,b^   HepG2 ^f^ (IC~50~, nM)   SI ^g^ HepG2/D6   RI ^h^ W2/D6                     
  ------------- -------------------------------------------------------------------- ------------------------ ----------------- -------------- ---------- ------ ------
  **37**        ![](molecules-22-00343-i017.jpg)                                     49                       26                60             \> 30605   624    0.5
  **38**        ![](molecules-22-00343-i018.jpg)                                     84                       20                43             2564       30     0.2
  **39**        ![](molecules-22-00343-i019.jpg)                                     59                       46                52             \> 5792    98     0.8
  **40**        ![](molecules-22-00343-i020.jpg)                                     80                       41                54             6702       84     0.5
  **41**        ![](molecules-22-00343-i021.jpg)                                     27                       13                20             2415       89     0.5
  **42**        ![](molecules-22-00343-i022.jpg)                                     55                       12                30             2092       38     0.2
  **43**        ![](molecules-22-00343-i023.jpg)                                     4                        106               34             8153       2038   26
  **44**        ![](molecules-22-00343-i024.jpg)                                     101                      74                54             4085       40     0.7
  **46**        ![](molecules-22-00343-i025.jpg)                                     7                        5                 13             2570       367    0.7
  **52**        ![](molecules-22-00343-i026.jpg)                                     177                      259               274            9230       52     1.5
  **CQ ^i^**    ![](molecules-22-00343-i027.jpg)                                     15 (6)                   595 (5)           206 (5)                          39.7
  **MFQ ^i^**   ![](molecules-22-00343-i028.jpg)                                     23 (6)                   7 (5)             55 (5)                           0.3

^a^ Antiplasmodial IC~50~ values (nM) (Malaria SYBR Green Fluorescence Assay) for isolates and clones of *P. falciparum*; ^b^ All in vitro experiments were done as technical quadruplicates, mean values are given; ^c^ CQ susceptible *P. falciparum* African D6 clone; ^d^ CQ resistant *P. falciparum* Indochina W2 clone; ^e^ *P. falciparum* multidrug resistant TM91C235 strain (Thailand). ^f^ Hepatocellular carcinoma; ^g^ Selectivity index; ^h^ Resistance index; ^i^ Control drugs: CQ as diphosphate; MFQ as HCl salt (number of replicates given in parentheses).

molecules-22-00343-t003_Table 3

###### 

In Vivo Antimalarial Activity ^a,b^.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Comp.                   mg/kg/Day                                            Parasitemia (Day: \# Mice, %Parasitemia)              Mice Dead/Day Died   Mice Alive on Day 31   Mean Survival Time (MST, Days)
  ----------------------- ---------------------------------------------------- ----------------------------------------------------- -------------------- ---------------------- --------------------------------
  **1**                   20 ^c^                                               D3: 5 mice positive, 0.6%--2.4%;\                     2/11                 0/5                    16.8
                                                                               D7: 2 mice negative, 3 mice positive, 0.1%--0.2%;\                                                
                                                                               D11: 3 mice positive, 0.8%--1.9%;\                                                                
                                                                               D14: 2 mice positive, 1.6%--3.7%;\                                                                
                                                                               D18: 1 mouse positive, 6%;\                                                                       
                                                                               D21: 1 mouse positive, 27%;\                                                                      
                                                                               D25: 1 mouse positive, 63%;\                                                                      
                                                                               D28: 1 mouse positive, 66%                                                                        

  1/14                                                                                                                                                                           

  1/18                                                                                                                                                                           

  1/30                                                                                                                                                                           

  40 ^c^                  D3: 5 mice positive, 0.4%--0.9%;\                    1/15                                                  0/5                  19.4                   
                          D7: 5 mice negative;\                                                                                                                                  
                          D11: 5 mice negative;\                                                                                                                                 
                          D14: 5 mice positive, 0.6%--2.4%;\                                                                                                                     
                          D18: 1 mouse positive, 2.2%;\                                                                                                                          
                          D21: 1 mouse positive, 7.3%;\                                                                                                                          
                          D25: 1 mouse positive, 37%;\                                                                                                                           
                          D28: 1 mouse positive, 53%                                                                                                                             

  1/16                                                                                                                                                                           

  2/18                                                                                                                                                                           

  1/30                                                                                                                                                                           

  80 ^c^                  D3: 4 mice positive, 0.7%--1.1%;\                    3/18                                                  0/4                  18.2                   
                          D7: 4 mice negative;\                                                                                                                                  
                          D11: 4 mice negative;\                                                                                                                                 
                          D14: 4 mice positive, 0.1%--0.5%;\                                                                                                                     
                          D18: 1 mouse positive, 2.3%                                                                                                                            

  1/19                                                                                                                                                                           

  160                     D3: 5 mice positive, 0.3%--0.9%;\                                                                          5/5                  \>31                   
                          D7--D31: 5 mice negative                                                                                                                               

  **25**                  160                                                  D3: 4 mice positive, 0.4%--0.6%;\                     2/17                 1/4                    20.8
                                                                               D7: 4 mice positive, 0.2%--0.4%;\                                                                 
                                                                               D10: 4 mice positive, 0.3%--0.6%;\                                                                
                                                                               D14: 4 mice positive, 0.5%--0.8%;\                                                                
                                                                               D17: 2 mouse positive, 1.5%--3.7%;\                                                               
                                                                               D21: 1 mouse positive, 2.7%;\                                                                     
                                                                               D24: 1 mouse positive, 52%;\                                                                      
                                                                               D28: 1 mouse positive, 72%;\                                                                      
                                                                               D31: 1 mouse positive, 79%                                                                        

  1/18                                                                                                                                                                           

  **42**                  160                                                  D3: 5 mice positive, 0.2%--0.6%;\                     1/9                  0/5                    18.6
                                                                               D7: 5 mice positive, 0.2%--10%;\                                                                  
                                                                               D10: 4 mice positive, 9.2%--15%;\                                                                 
                                                                               D14: 3 mice positive, 12.8%--47%;\                                                                
                                                                               D17: 3 mice positive, 50%--60%;\                                                                  
                                                                               D21: 2 mice positive, 64%--70%;\                                                                  
                                                                               D24: 1 mouse positive, 75%                                                                        

  1/13                                                                                                                                                                           

  1/20                                                                                                                                                                           

  1/23                                                                                                                                                                           

  1/28                                                                                                                                                                           

  **46**                  40 ^c^                                               D3: 5 mice positive, 0.6%--2.2%;\                     1/10                 0/5                    15.8
                                                                               D7: 1 mouse negative, 4 mice positive, 0.2%--0.4%;\                                               
                                                                               D10: 4 mice positive, 1.6%--4.9%;\                                                                
                                                                               D14: 2 mice positive, 8.1%--12%;\                                                                 
                                                                               D18: 2 mice positive, 16%--20%;\                                                                  
                                                                               D21: 2 mice positive, 22%--41%;\                                                                  
                                                                               D25: 1 mouse positive, 43%                                                                        

  2/11                                                                                                                                                                           

  1/22                                                                                                                                                                           

  1/25                                                                                                                                                                           

  80 ^c^                  D3: 5 mice positive, 0.8%--2.3%;\                    1/7                                                   0/5                  14.4                   
                          D7: 2 mice negative, 2 mice positive, 0.1%--0.2%;\                                                                                                     
                          D10: 4 mice positive, 0.2%--6.6%;\                                                                                                                     
                          D14: 1 mouse positive, 4.7%;\                                                                                                                          
                          D18: 1 mouse positive, 12%;\                                                                                                                           
                          D21: 1 mouse positive, 35%;\                                                                                                                           
                          D25: 1 mouse positive, 41%                                                                                                                             

  1/12                                                                                                                                                                           

  1/13                                                                                                                                                                           

  1/14                                                                                                                                                                           

  1/26                                                                                                                                                                           

  **CQ**                  160                                                  D3: 5 mice positive, 0.3%--0.8%;\                                          5/5                    \>31
                                                                               D6-D31: 5 mice negative                                                                           

  **Infected controls**   0                                                    All mice died on day 7--8                                                                         
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Groups of five *P*. *berghei* (ANKA strain) infected mice were treated per os (p.o.) once per day on days 3--5 postinfection with aminoquinolines suspended in 0.5% hydroxyethylcellulose-0.1% Tween 80. Mice alive on day 31 with no parasites in a blood film are considered cured; ^b^ All compounds were tested in separate experiments (mice groups) for toxicity. None exerted any toxic effect when dosed orally at 160 mg/kg/day × 3 days; ^c^ Groups of five *P*. *berghei* (ANKA strain) infected mice were treated per os (p.o.) once per day on days on 3--6 postinfection with aminoquinolines suspended in 0.5% hydroxyethylcellulose-0.1% Tween 80. Mice alive on day 31 with no parasites in a blood film are considered cured.
